124 related articles for article (PubMed ID: 35338353)
1. Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial.
Chi JT; Lin PH; Tolstikov V; Howard L; Chen EY; Bussberg V; Greenwood B; Narain NR; Kiebish MA; Freedland SJ
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):770-777. PubMed ID: 35338353
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).
Freedland SJ; Allen J; Jarman A; Oyekunle T; Armstrong AJ; Moul JW; Sandler HM; Posadas E; Levin D; Wiggins E; Howard LE; Wu Y; Lin PH
Clin Cancer Res; 2020 Jun; 26(12):3035-3043. PubMed ID: 32108029
[TBL] [Abstract][Full Text] [Related]
3. Weight loss via a low-carbohydrate diet improved the intestinal permeability marker, zonulin, in prostate cancer patients.
Lin PH; Howard L; Freedland SJ
Ann Med; 2022 Dec; 54(1):1221-1225. PubMed ID: 35486445
[TBL] [Abstract][Full Text] [Related]
4. The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
Chi JT; Lin PH; Tolstikov V; Oyekunle T; Alvarado GCG; Ramirez-Torres A; Chen EY; Bussberg V; Chi B; Greenwood B; Sarangarajan R; Narain NR; Kiebish MA; Freedland SJ
Prostate; 2021 Jul; 81(10):618-628. PubMed ID: 33949711
[TBL] [Abstract][Full Text] [Related]
5. Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer.
Freedland SJ; Howard LE; Ngo A; Ramirez-Torres A; Csizmadi I; Cheng S; Mack A; Lin PH
J Urol; 2021 Dec; 206(6):1411-1419. PubMed ID: 34259565
[TBL] [Abstract][Full Text] [Related]
6. A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.
Freedland SJ; Howard L; Allen J; Smith J; Stout J; Aronson W; Inman BA; Armstrong AJ; George D; Westman E; Lin PH
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):428-437. PubMed ID: 30664736
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of serum bone sialoprotein and prostate-specific antigen doubling time in patients with bone metastasis of prostate cancer.
Wang Y; Zhang XF; Dai J; Zheng YC; Zhang MG; He JJ
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):559-562. PubMed ID: 23904377
[TBL] [Abstract][Full Text] [Related]
8. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
[TBL] [Abstract][Full Text] [Related]
9. Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy.
Cheney MD; Zhang D; Chen MH; Loffredo MJ; Richie JP; D'Amico AV
Clin Genitourin Cancer; 2015 Aug; 13(4):338-343. PubMed ID: 25862320
[TBL] [Abstract][Full Text] [Related]
10. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
13. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group.
Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2009 Dec; 104(11):1604-9. PubMed ID: 19549124
[TBL] [Abstract][Full Text] [Related]
14. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.
Paller CJ; Olatoye D; Xie S; Zhou X; Denmeade SR; Eisenberger MA; Antonarakis ES; Carducci MA; Rosner GL
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):28-33. PubMed ID: 24100642
[TBL] [Abstract][Full Text] [Related]
15. The Low-Carbohydrate Diet: Short-Term Metabolic Efficacy Versus Longer-Term Limitations.
Barber TM; Hanson P; Kabisch S; Pfeiffer AFH; Weickert MO
Nutrients; 2021 Apr; 13(4):. PubMed ID: 33916669
[TBL] [Abstract][Full Text] [Related]
16. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract][Full Text] [Related]
17. PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
Markowski MC; Chen Y; Feng Z; Cullen J; Trock BJ; Suzman D; Antonarakis ES; Paller CJ; Rosner I; Han M; Walsh PC; Partin AW; Eisenberger M
Clin Genitourin Cancer; 2019 Dec; 17(6):470-475.e1. PubMed ID: 31530439
[TBL] [Abstract][Full Text] [Related]
18. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
J Clin Oncol; 2007 May; 25(13):1765-71. PubMed ID: 17470867
[TBL] [Abstract][Full Text] [Related]
19. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
[TBL] [Abstract][Full Text] [Related]
20. Relationship of three different types of low-carbohydrate diet to cardiometabolic risk factors in a Japanese population: the INTERMAP/INTERLIPID Study.
Nakamura Y; Ueshima H; Okuda N; Miura K; Kita Y; Miyagawa N; Yoshita K; Nakagawa H; Sakata K; Saitoh S; Okamura T; Okayama A; Choudhry SR; Rodriguez B; Masaki KH; Chan Q; Elliott P; Stamler J
Eur J Nutr; 2016 Jun; 55(4):1515-24. PubMed ID: 26119583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
